Aspergillus terreus: An emerging amphotericin B-resistant oppurtunistic mold in patients with hematologic malignancies

Cancer

Volumn 101, Issue 7, 2004, Pages 1594-1600

  Hachem, Ray Y ^a   Kontoyiannis, Dimitrios P ^a   Boktour, Maha R ^a   Afif, Claude ^a,b   Cooksley, Catherine ^a   Bodey, Gerald P ^a   Chatzinikolaou, Ioannis ^a   Perego, Cheryl ^a   Kantarjian, Hagop M ^a   Raad, Issam J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF BALAMAND   (Lebanon)

Author keywords

Aspergillus fumigatus; Aspergillus terreus; Cancer; Lipid preparation; Neutropenia; Patients

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ITRACONAZOLE; POSACONAZOLE; PREDNISONE;

ADULT; AGED; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; FUNGUS ISOLATION; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; INFECTION RISK; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MOULD; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT FAILURE;

ADULT; AGED; AMPHOTERICIN B; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TRIAZOLES;

EID: 4844228685     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20554     Document Type: Review

References (31)

1. Denning DW. Invasive aspergillosis in immunocompromised patients. Curr Opin Infect Dis. 1994;7:456-462.
2. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis. 2002;21:161-172.
3. Denning DW. Invasive apergillosis. Clin Infect Dis. 1998;26: 781-805.
4. Andriole VT. Infections with Aspergillus species. Clin Infect Dis. 1993;17 Suppl 2:S481-S486.
5. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997; 175:1459-1466.
6. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608-615.
7. Iwen PC, Reed EC, Armitage JO, et al. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol. 1993;14:131-139.
8. Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis. 1998;26:1092-1097.
9. Torres HA, Rivero GA, Lewis RE, Hachem R, Raad II, Kontoyiannis DP. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis. 2003;46:25-28.
10. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001;7 Suppl 2:8-24.
11. Lass-Florl C, Rath PM, Niederwieser D, et al. Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J Hosp Infect. 2000;46:31-35.
12. Wald A, Leisenring W, Van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997; 175:1459-1466.
13. Flynn PM, Williams BG, Hetherington SV, Williams BF, Giannini MA, Pearson TA. Aspergillus terreus during hospital renovation. Infect Control Hosp Epidemiol. 1993;14: 363-365.
14. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46:1032-1037.
15. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol. 1999;37:2343-2345.
16. Ascioglu S, Rex JH, DePauw JE, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002; 34:7-14.
17. Sutton DA, Fothergill AW, Rinaldi MG, editors. Guide to clinically significant fungi. Baltimore: Williams & Wilkins, 1998.
18. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Proposed Standard M38-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
19. Moore CK, Hellreich MA, Coblenty CL, Roggli VL. Aspergillus terreus as a cause of invasive pulmonary aspergillosis. Chest. 1988;94:889-891.
20. Tritz DM, Woods GL. Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts. Clin Infect Dis. 1993;16:118-122.
21. Kalina PH, Campbell JR. Aspergillus terreus endophthalmitis in a patient with chronic lymphocytic leukemia. Arch Ophthalmol. 1991;109:102-103.
22. Hogan LH, Klein BS, Levitz SM. Virulence factors of medically important fungi. Clin Microbiol Rev. 1996;9:469-488.
23. Rodriguez-Adrian LJ, Grazziuti ML, Rex JH, Anaissie EJ. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis. 1998;26:1270-1278.
24. Schaffner A. Macrophage-Aspergillus interactions. Immunol Ser. 1994;60:545-552.
25. Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol. 2003;41:5525-5529.
26. Dannaoui E, Borel E, Persat F, Piens MA, Picot S. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol. 2000;49:601-606.
27. Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis. 2003;188:305-319.
28. Lass-Florl C, Kofler G, Kropshofer G, et al. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother. 1998;42:497-502.
29. Loeffler J, Stevens DA. Antifungal drug resistance. Clin Infect Dis. 2003;36(Suppl 1):S31-S41.
30. Kontoyiannis DP, Lewis RE. Antffungal drug resistance of pathogenic fungi. Lancet. 2002;359:1135-1144.
31. Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 1997;41:696-698.